StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Tuesday morning. The firm issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Performance

Shares of NASDAQ BIOL opened at $0.01 on Tuesday. The firm’s 50 day moving average price is $0.01 and its 200-day moving average price is $0.04. The company has a market cap of $293,981.60, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.